‘The UK is leading a two speed Europe’ (McKinsey & Company, Biotech in Europe: Scaling Innovation May 20, 2019).
One of the key findings and contrary to the received wisdom, is that the UK is totally smashing it on all measures as a Biotech hot spot according to research presented at BioEquity Europe in Barcelona by McKinsey & Company looking at where's hot and where's not.
Of the 1,000 European Biotechs established since 2012 the UK is leading by a country mile and represents 35% of all new Biotechs and according to the report and is leading a two speed Europe (with Germany, France and Spain in relative decline).
Leading gene therapy manufacturer recognised as part of Oxfordshire Business Awards
Oxford, UK, June 18 2019 - Its work on life-changing treatments for serious diseases has earned Oxford Biomedica, a leading gene and cell therapy group, The Oxford Science Park Innovation Award 2019.
Just this week, Public Health England said that every one person who misses a vaccination is "one too many". There have been 795 cases of mumps in the first three months of 2019, compared with 1031 cases in the whole of 2018. Measles is not far behind in terms of making a comeback, but how does the disease get such a grip, and why does it spread so fast? Check out this video from Stat news to find out more about how measles gets a grip - and remember the most effective way to prevent it is by getting vaccinated.
UK life science certainly feels more Champions League Final (Spurs v Liverpool) than Eurovision (UK last place) this week. First, LifeArc has announced that it has sold most of its royalty interest in the blockbuster drug Keytruda for $1.3bn (£1.02bn) and plans to invest the windfall in developing new treatments. The sale was made to the Canada Pension Plan Investment Board, one of the world’s largest retirement funds. We were thrilled that recently-appointed LifeArc CEO, Melanie Lee, was the recipient of our lifetime achievement award at the BIA Gala Dinner in January – it’s fantastic to see her leading the way on LifeArc’s monetization process. This is great news for the UK life sciences ecosystem, research and patients. You can read more about this in the Financial Times.
Professor Jennifer Doudna, one the pioneers of Crispr-Cas9 gene editing explains how this important discovery enables precise changes to our DNA , which can be used to correct mutations that cause genetic disease and completely eradicate it from a germline. Doudna raises the 4 key issues of debate around this revolutionary discovery and suggests what will have the most immediate impact.
Locate Bio Ltd has received an additional £2.0 million of investment from Mercia Technologies PLC and its third party fund, the Midlands Engine Investment Fund to expand the application of its technologies, including its promising gene therapy technology IntraStem™, into new high value therapy areas to both broaden its in-house development pipeline and provide additional partnering opportunities.
One of the most high profile research fields in modern healthcare is that of cancer care. The leaps in medicine mean that in the UK, cancer survival has doubled in the last 40 years. What’s more, 50% of people diagnosed currently survive for 10 years or more (CRUK, 2010–11). These are incredible statistics that show the real-world effects of better cancer research and care. But, as the incidence of new diagnoses is rising, we need to do more.
The latest decision concerning Supplementary Protection Certificates (SPCs) was handed down by the CJEU in the Abraxis Bioscience case (C-443/17) on 21 March. The BIA’s IP Advisory Committee (IPAC) provided informal views on behalf of the sector to the UK Intellectual Protection Office (IPO) regarding this case, to inform the UK Government’s representations to the CJEU. Andrew Hutchinson of Simmons & Simmons and a member of IPAC has provided the following analysis for BIA members.